title: Imatinib mesylate and its potential implications for gynecologic cancers.
abstract: Among gynecologic malignancies, ovarian carcinoma is the most frequent cause of death, with the majority of patients presenting at advanced stage. There is a high rate of recurrence despite first-line chemotherapy. Sarcoma of the uterus, while accounting for a small percent of uterine cancers, is also associated with a high-recurrence rate and poor overall survival. Therefore, the development of novel treatment strategies is paramount. Imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corp., East Hanover, NJ) is a tyrosine kinase inhibitor with activity against abl, c-kit, and platelet derived growth factor receptor (PDGFR), and is approved for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumor. Preclinical data provides evidence for c-kit and PDGFR expression in ovarian epithelial carcinomas and uterine sarcomas and have led to clinical trials evaluating the use of imatinib in these malignancies. Additionally, inhibition of PDGFR signaling has been proposed as an effective mechanism of chemotherapy by lowering tumor interstitial fluid pressure. Recent data have also suggested benefit with metronomic scheduling of cytotoxic agents at lower doses at more frequent dosing intervals, in combination with other targeted therapies. While activity of this agent remains to be established, further studies of imatinib in gynecologic malignancies are warranted, to demonstrate not only single-agent activity and the enhancement of cytotoxicity of other antineoplastic agents.
authors.affiliation: Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
authors.forename: Holly
authors.initials: H
authors.lastname: Dushkin
authors.forename: Russell J
authors.initials: RJ
authors.lastname: Schilder
mesh_terms: D001549:Benzamides; D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D020714:Maximum Tolerated Dose; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate
references.citation: J Clin Invest. 2000 Apr;105(8):1045-7
references.pmid: 10772648
references.citation: Cancer Res. 1991 Dec 15;51(24):6691-4
references.pmid: 1742743
references.citation: Semin Oncol. 2002 Jun;29(3 Suppl 8):3-6
references.pmid: 12082646
references.citation: Nat Rev Cancer. 2004 Oct;4(10):806-13
references.pmid: 15510161
references.citation: N Engl J Med. 2001 Apr 5;344(14):1052-6
references.pmid: 11287975
references.citation: Cancer. 2003 Aug 15;98(4):758-64
references.pmid: 12910520
references.citation: CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47
references.pmid: 11814064
references.citation: Cancer Res. 2002 Oct 1;62(19):5476-84
references.pmid: 12359756
references.citation: Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3779-87
references.pmid: 14506171
references.citation: N Engl J Med. 2002 Aug 15;347(7):472-80
references.pmid: 12181401
references.citation: Cancer Res. 1992 Nov 15;52(22):6371-4
references.pmid: 1423283
references.citation: Eur J Cancer. 1991;27(9):1095-9
references.pmid: 1835616
references.citation: J Reprod Med. 2004 Feb;49(2):71-5
references.pmid: 15018431
references.citation: J Clin Invest. 2000 Apr;105(8):R15-24
references.pmid: 10772661
references.citation: N Engl J Med. 2001 Apr 5;344(14):1031-7
references.pmid: 11287972
references.citation: Clin Cancer Res. 2004 Jan 15;10 (2):681-90
references.pmid: 14760091
references.citation: Cancer Res. 1992 Apr 1;52(7):1993-5
references.pmid: 1551128
references.citation: Cancer Res. 1987 Jun 15;47(12):3039-51
references.pmid: 3555767
references.citation: Hum Pathol. 1998 May;29(5):498-504
references.pmid: 9596274
references.citation: J Clin Invest. 2003 May;111(9):1287-95
references.pmid: 12727920
references.citation: N Engl J Med. 2001 Apr 5;344(14):1038-42
references.pmid: 11287973
references.citation: Biol Reprod. 2000 Jun;62(6):1600-9
references.pmid: 10819761
references.citation: Semin Oncol. 2001 Oct;28(5 Suppl 17):27-33
references.pmid: 11740804
references.citation: Oncogene. 2002 Sep 12;21(41):6289-98
references.pmid: 12214269
references.citation: Eur J Cancer. 1997 May;33(6):907-11
references.pmid: 9291814
references.citation: Semin Oncol. 2004 Apr;31(2 Suppl 6):18-23
references.pmid: 15176000
references.citation: Physiol Rev. 1999 Oct;79(4):1283-316
references.pmid: 10508235
references.citation: Int J Cancer. 2000 May 20;89(3):242-50
references.pmid: 10861500
references.citation: Cancer Res. 1993 Oct 1;53(19):4550-4
references.pmid: 8402626
references.citation: Cancer Res. 2000 Apr 1;60(7):1878-86
references.pmid: 10766175
references.citation: Semin Oncol. 2004 Apr;31(2 Suppl 6):4-11
references.pmid: 15175998
references.citation: Semin Oncol. 2002 Feb;29(1 Suppl 1):32-42
references.pmid: 11840418
references.citation: Nat Med. 1996 May;2(5):561-6
references.pmid: 8616716